JP5739816B2 - Ｔｆｐｉインヒビターおよび使用法 - Google Patents

Ｔｆｐｉインヒビターおよび使用法 Download PDF

Info

Publication number
JP5739816B2
JP5739816B2 JP2011542550A JP2011542550A JP5739816B2 JP 5739816 B2 JP5739816 B2 JP 5739816B2 JP 2011542550 A JP2011542550 A JP 2011542550A JP 2011542550 A JP2011542550 A JP 2011542550A JP 5739816 B2 JP5739816 B2 JP 5739816B2
Authority
JP
Japan
Prior art keywords
amino acid
group
peptide
acid selected
tfpi
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2011542550A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012512915A5 (enExample
JP2012512915A (ja
Inventor
ミヒャエル ドカル，
ミヒャエル ドカル，
ハルトムート エルリッヒ，
ハルトムート エルリッヒ，
フリードリヒ シェイフリンガー，
フリードリヒ シェイフリンガー，
ウルフ ライマー，
ウルフ ライマー，
ウルリヒ ライネケ，
ウルリヒ ライネケ，
トマス ポラコフスキ，
トマス ポラコフスキ，
エーベルハルト シュナイダー，
エーベルハルト シュナイダー，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Baxter Healthcare SA
Baxter International Inc
Original Assignee
Baxter Healthcare SA
Baxter International Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baxter Healthcare SA, Baxter International Inc filed Critical Baxter Healthcare SA
Publication of JP2012512915A publication Critical patent/JP2012512915A/ja
Publication of JP2012512915A5 publication Critical patent/JP2012512915A5/ja
Application granted granted Critical
Publication of JP5739816B2 publication Critical patent/JP5739816B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • A61K47/551—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds one of the codrug's components being a vitamin, e.g. niacinamide, vitamin B3, cobalamin, vitamin B12, folate, vitamin A or retinoic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/555—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound pre-targeting systems involving an organic compound, other than a peptide, protein or antibody, for targeting specific cells
    • A61K47/557—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound pre-targeting systems involving an organic compound, other than a peptide, protein or antibody, for targeting specific cells the modifying agent being biotin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
JP2011542550A 2008-12-19 2009-12-21 Ｔｆｐｉインヒビターおよび使用法 Active JP5739816B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13927208P 2008-12-19 2008-12-19
US61/139,272 2008-12-19
PCT/US2009/069060 WO2010071894A2 (en) 2008-12-19 2009-12-21 Tfpi inhibitors and methods of use

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015089324A Division JP6095717B2 (ja) 2008-12-19 2015-04-24 Ｔｆｐｉインヒビターおよび使用法

Publications (3)

Publication Number Publication Date
JP2012512915A JP2012512915A (ja) 2012-06-07
JP2012512915A5 JP2012512915A5 (enExample) 2013-01-24
JP5739816B2 true JP5739816B2 (ja) 2015-06-24

Family

ID=42269298

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2011542550A Active JP5739816B2 (ja) 2008-12-19 2009-12-21 Ｔｆｐｉインヒビターおよび使用法
JP2015089324A Active JP6095717B2 (ja) 2008-12-19 2015-04-24 Ｔｆｐｉインヒビターおよび使用法
JP2017024988A Active JP6567577B2 (ja) 2008-12-19 2017-02-14 Ｔｆｐｉインヒビターおよび使用法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2015089324A Active JP6095717B2 (ja) 2008-12-19 2015-04-24 Ｔｆｐｉインヒビターおよび使用法
JP2017024988A Active JP6567577B2 (ja) 2008-12-19 2017-02-14 Ｔｆｐｉインヒビターおよび使用法

Country Status (16)

Country Link
US (3) US8466108B2 (enExample)
EP (1) EP2379096B1 (enExample)
JP (3) JP5739816B2 (enExample)
KR (3) KR101977846B1 (enExample)
CN (2) CN104984319B (enExample)
AU (1) AU2009327338B2 (enExample)
BR (2) BRPI0922344A2 (enExample)
CA (1) CA2747721C (enExample)
DK (1) DK2379096T3 (enExample)
ES (1) ES2773766T3 (enExample)
HR (1) HRP20192282T8 (enExample)
HU (1) HUE046951T2 (enExample)
LT (1) LT2379096T (enExample)
NZ (2) NZ593815A (enExample)
SI (1) SI2379096T1 (enExample)
WO (1) WO2010071894A2 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5739816B2 (ja) 2008-12-19 2015-06-24 バクスター・インターナショナル・インコーポレイテッドＢａｘｔｅｒ Ｉｎｔｅｒｎａｔｉｏｎａｌ Ｉｎｃｏｒｐ０Ｒａｔｅｄ Ｔｆｐｉインヒビターおよび使用法
KR101745394B1 (ko) * 2008-12-22 2017-06-09 노보 노르디스크 에이/에스 조직 인자 경로 억제자에 대한 항체
WO2011047215A1 (en) * 2009-10-14 2011-04-21 Aileron Therapeutics, Inc. Improved peptidomimetic macrocycles
SG183443A1 (en) 2010-03-01 2012-09-27 Bayer Healthcare Llc Optimized monoclonal antibodies against tissue factor pathway inhibitor (tfpi)
WO2011115712A2 (en) 2010-03-19 2011-09-22 Baxter International Inc Tfpi inhibitors and methods of use
CN103080135B (zh) 2010-06-30 2017-06-13 诺沃—诺迪斯克有限公司 能够特异性结合组织因子途径抑制剂的抗体
US9228022B2 (en) 2010-06-30 2016-01-05 Novo Nordisk A/S Antibodies that are capable of specifically binding tissue factor pathway inhibitor
TWI483733B (zh) * 2011-02-11 2015-05-11 Baxter Int Ｔｆｐｉ抑制劑及使用方法
EP2673364A1 (en) * 2011-02-11 2013-12-18 Baxter International Inc Aptamers to tissue factor pathway inhibitor and their use as bleeding disorder therapeutics
US9045526B2 (en) 2011-06-23 2015-06-02 The Regents Of The University Of Michigan Compound and method for modulating opioid receptor activity
SI2827883T1 (sl) * 2012-03-21 2019-08-30 Baxalta GmbH Inhibitorji TFPI in postopki uporabe
CN104215707B (zh) * 2014-09-02 2016-01-20 福建中医药大学 栝楼桂枝汤的质量检测方法
WO2016137108A1 (en) 2015-02-25 2016-09-01 Mogam Biotechnology Institute Novel antibody binding to tfpi and composition comprising the same
PE20240142A1 (es) * 2015-08-19 2024-02-01 Pfizer Anticuerpos inhibidores via del factor tisular y usos de los mismos
HUE070009T2 (hu) 2019-07-08 2025-05-28 3B Pharmaceuticals Gmbh Fibroblaszt aktiváló protein ligandumot tartalmazó vegyületek és alkalmazásuk
JP7152084B1 (ja) * 2022-02-22 2022-10-12 株式会社血栓トランスレーショナルリサーチラボ 組織因子経路インヒビターの抗凝固活性の検査試薬、検査試薬セット、および検査方法

Family Cites Families (126)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS607193B2 (ja) 1978-01-10 1985-02-22 トヨタ自動車株式会社 熱風循環型乾燥炉
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
JPS5733175A (en) 1980-07-31 1982-02-23 Mitsubishi Electric Corp Transmitter for signal of elevator
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
EP0206448B1 (en) * 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US4966852A (en) * 1987-07-23 1990-10-30 Monsanto Company DNA clone of human tissue factor inhibitor
IL87171A (en) 1987-11-23 1995-08-31 Monsanto Co cDNA of human tissue factor inhibitor
US5663143A (en) 1988-09-02 1997-09-02 Dyax Corp. Engineered human-derived kunitz domains that inhibit human neutrophil elastase
US5219994A (en) * 1988-11-08 1993-06-15 W. Alton Jones Cell Science Center, Inc. Inhibitor of tissue factor activity
EP0514464A4 (en) * 1990-02-08 1993-04-28 Magainin Sciences, Inc. Biologically active amphiphilic peptides and method of inhibiting growth of target cells, virus or virally-infected cell
US5466468A (en) 1990-04-03 1995-11-14 Ciba-Geigy Corporation Parenterally administrable liposome formulation comprising synthetic lipids
DK146190D0 (da) 1990-06-15 1990-06-15 Novo Nordisk As Hidtil ukendte forbindelser
US5622988A (en) 1990-06-15 1997-04-22 Novo Nordisk A/S Use of a low molecular weight metabolite from fungus for reducing prolonged coagulation time
US5849703A (en) * 1990-08-27 1998-12-15 G. D. Searle & Co. Pre-formed anticoagulant heparin/TFPI complexes
DK261490D0 (da) 1990-10-31 1990-10-31 Novo Nordisk As New pharmaceutical compound
US5197973A (en) * 1990-12-14 1993-03-30 Creative Biomolecules, Inc. Synthetic bioadhesive
US5399363A (en) 1991-01-25 1995-03-21 Eastman Kodak Company Surface modified anticancer nanoparticles
JPH04252954A (ja) 1991-01-29 1992-09-08 Asahi Chem Ind Co Ltd タンパクの測定方法、試薬及びキット
US5997864A (en) * 1995-06-07 1999-12-07 Novo Nordisk A/S Modified factor VII
US5833982A (en) 1991-02-28 1998-11-10 Zymogenetics, Inc. Modified factor VII
EP0539975A1 (en) * 1991-10-31 1993-05-05 Teijin Limited Method for immunological assay of free lipoprotein-associated coagulation inhibitor (LACI) and kit therefor
JPH067193A (ja) 1991-11-29 1994-01-18 Teijin Ltd モノクローナル抗体
IL104325A (en) * 1992-01-07 2000-10-31 Novo Nordisk As Variants of human kunitz-type protease inhibitor domain II of tissue factor pathway inhibitor (TFPI) pharmaceutical compositions containing them a DNA construct encoding them their expression vectors a cell containing said DNA constructs and methods for the production of all the above
IL104314A0 (en) 1992-01-07 1993-05-13 Novo Nordisk As Human kunitz-type protease inhibitor and variants thereof,their production and pharmaceutical compositions containing them
IL104324A0 (en) 1992-01-07 1993-05-13 Novo Nordisk As Variant of human kunitz-type protease inhibitor
IL104327A0 (en) * 1992-01-07 1993-05-13 Novo Nordisk As Variant of human kunitz-type protease inhibitor
IL104326A0 (en) 1992-01-07 1993-05-13 Novo Nordisk As Variant of human kunitz-type protease inhibitor
EP0651655A4 (en) 1992-07-24 1996-05-29 Oklahoma Med Res Found REDUCTION OF MICROVASCULAR BLEEDING DURING SURGERY BY BLOCKING PROTEIN C ACTIVATION
JPH06153985A (ja) 1992-11-16 1994-06-03 Teijin Ltd モノクローナル抗体
US5439686A (en) * 1993-02-22 1995-08-08 Vivorx Pharmaceuticals, Inc. Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor
PT693924E (pt) * 1993-02-22 2004-09-30 American Biosciences Processos para administracao (in vivo) de substancias biologicas e composicoes utilizadas nestes processos
JP3929484B2 (ja) * 1993-09-14 2007-06-13 ジェネンテック・インコーポレーテッド エコチンおよびその同族体を含む医薬的組成物
US5455338A (en) 1993-11-05 1995-10-03 Zymogenetics, Inc. DNA encoding novel human kunitz-type inhibitors and methods relating thereto
ES2229236T3 (es) 1994-01-11 2005-04-16 Dyax Corporation Inhibidores de la plasmina humana derivados de los dominios de kunitz.
US5902582A (en) 1995-09-05 1999-05-11 Chiron Corporation Use of TFPI inhibitor for treatment of cancer
JP3681206B2 (ja) 1995-12-26 2005-08-10 株式会社三菱化学ヤトロン 抗ファクターＸａ・ティシュファクターパスウェイインヒビター複合体モノクローナル抗体及びその使用
US6262233B1 (en) * 1997-01-31 2001-07-17 Human Genome Sciences, Inc. Tissue factor pathway inhibitor-3
US20050032690A1 (en) * 1997-09-10 2005-02-10 Rojkjaer Lisa Payne Factor VII polypeptides for preventing formation of inhibitors in subjects with haemophilia
CA2320429C (en) * 1998-02-18 2011-04-19 Harbor-Ucla Research And Education Institute Antimicrobial peptides and derived metapeptides
JP2000128803A (ja) 1998-10-19 2000-05-09 Shionogi & Co Ltd ティッシュ・ファクター・パスウェイ・インヒビター−２抗体
AU3395900A (en) * 1999-03-12 2000-10-04 Human Genome Sciences, Inc. Human lung cancer associated gene sequences and polypeptides
JP2003505678A (ja) 1999-07-23 2003-02-12 ザ スクリップス リサーチ インスティテュート 全血の凝固因子活性を測定する方法
US6180607B1 (en) * 1999-08-05 2001-01-30 Christopher Davies Protein having proteinase inhibitor activity
US6458387B1 (en) 1999-10-18 2002-10-01 Epic Therapeutics, Inc. Sustained release microspheres
JP2003515535A (ja) 1999-11-16 2003-05-07 ザ ゼネラル ホスピタル コーポレーション 腫瘍関連抗原発現を調節するための組成物および方法
US6821775B1 (en) 2000-02-11 2004-11-23 Genvec, Inc. Viral vector encoding pigment epithelium-derived factor
WO2001085198A1 (en) * 2000-05-10 2001-11-15 Novo Nordisk A/S tHARMACEUTICAL COMPOSITION COMPRISING A FACTOR VIIA AND A FACTOR XIII
US7015194B2 (en) * 2000-05-10 2006-03-21 Novo Nordisk A/S Pharmaceutical composition comprising factor VIIa and anti-TFPI
AU2001263215A1 (en) 2000-05-16 2001-11-26 Genentech Inc. Method for treating cartilage disorders
AU2002230390A1 (en) * 2000-10-05 2002-04-29 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Ixodes scapularis tissue factor pathway inhibitor
JP2004535153A (ja) * 2000-10-18 2004-11-25 インサイト・ゲノミックス・インコーポレイテッド プロテアーゼ
WO2002043580A2 (en) * 2000-10-27 2002-06-06 Epic Therapeutics, Inc. Production of microspheres
US20040142892A1 (en) * 2001-04-30 2004-07-22 The University Of British Columbia Autogene nucleic acids encoding a secretable RNA polymerase
US20030040480A1 (en) * 2001-07-20 2003-02-27 Rasmus Rojkjaer Pharmaceutical composition comprising factor VII polypeptides and factor XI polypeptides
AU2002354846B2 (en) 2001-07-20 2007-08-02 Novo Nordisk Health Care Ag Pharmaceutical composition comprising factor VII polypeptides and factor XI polypeptides
PT1418890E (pt) * 2001-08-16 2008-06-09 Baxter Int Formulações de micropartículas à base de propulsor
US20080026068A1 (en) 2001-08-16 2008-01-31 Baxter Healthcare S.A. Pulmonary delivery of spherical insulin microparticles
US20030056474A1 (en) * 2001-09-26 2003-03-27 Chieh Szu Chung Method of inspecting newly purchased or reground materials for making printed circuit boards
WO2003028840A2 (en) 2001-09-27 2003-04-10 Board Of Regents, The University Of Texas System Combined compositions and methods for tumor vasculature coagulation and treatment
US7291587B2 (en) * 2001-11-09 2007-11-06 Novo Nordisk Healthcare A/G Pharmaceutical composition comprising factor VII polypeptides and TAFI polypeptides
EP1446145A1 (en) 2001-11-09 2004-08-18 Novo Nordisk Health Care AG Pharmaceutical composition comprising factor vii polypeptides and tafi polypeptides
US20050214836A1 (en) * 2002-08-30 2005-09-29 Oncotherapy Science, Inc. Method of diagnosing ovarian endometriosis
WO2005029089A2 (en) 2003-09-24 2005-03-31 Oncotherapy Science, Inc. Method of diagnosing ovarian endometriosis using tfpi-2 protein
WO2004021861A2 (en) 2002-09-03 2004-03-18 Vit Lauermann Targeted release
EP1403638A1 (en) 2002-09-25 2004-03-31 Mondobiotech SA Molecular methods for diagnosing interstitial lung diseases
EP2290107A1 (en) 2003-01-07 2011-03-02 Dyax Corporation Kunitz domain library
EP1620567A1 (en) 2003-04-15 2006-02-01 Hans-Jürgen Thiesen Method for diagnosing rheumatoid arthritis or osteoarthritis
JP4399454B2 (ja) 2003-07-04 2010-01-13 ベイジンジンウェイフイゴンチェンジシュヨウシアンゴンシ 接触分解アルキレートの改質処理方法
KR101137785B1 (ko) * 2003-07-18 2012-04-25 백스터 인터내셔널 인코포레이티드 제어된 상 분리에 의해 제조된 작은 구형 입자의 제조방법, 이용 방법 및 조성물
US20070092452A1 (en) 2003-07-18 2007-04-26 Julia Rashba-Step Methods for fabrication, uses, compositions of inhalable spherical particles
US20050142205A1 (en) * 2003-07-18 2005-06-30 Julia Rashba-Step Methods for encapsulating small spherical particles prepared by controlled phase separation
WO2005009375A2 (en) * 2003-07-22 2005-02-03 Baxter International Inc. Small spherical particles of low molecular weight organic molecules and methods of preparation and use thereof
JP4824559B2 (ja) * 2003-09-09 2011-11-30 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト 凝固因子ｖｉｉポリペプチド
WO2005024006A2 (en) 2003-09-09 2005-03-17 Novo Nordisk Health Care Ag Coagulation factor vii polypeptides
WO2005034844A2 (en) * 2003-09-12 2005-04-21 Cleveland State University Exosite-directed thrombin inhibitors
DE502004005857D1 (de) 2003-09-29 2008-02-14 Hemoteq Ag Biokompatible, biostabile beschichtung von medizinischen oberflächen
US20090232866A1 (en) * 2003-10-07 2009-09-17 Mariann Pavone-Gyongyosi Oligopeptides as coating material for medical products
US20050181978A1 (en) * 2003-11-20 2005-08-18 Rasmus Rojkjaer Therapeutic use of factor XI
KR20060118486A (ko) 2003-11-20 2006-11-23 노보 노르디스크 헬스 케어 악티엔게젤샤프트 인자 ｘｉ의 치료적 사용
JP4885729B2 (ja) * 2003-11-20 2012-02-29 サノフィ パストゥール インコーポレイテッド 百日咳毒素を精製する方法およびそれに有用なペプチド
US20050147689A1 (en) 2003-12-30 2005-07-07 Egilmez Nejat K. Method for inhibiting the growth of gastrointestinal tract tumors
KR100891148B1 (ko) * 2004-02-28 2009-04-06 헤모텍 아게 의료용 표면의 생체적합성 코팅, 방법 및 그 용도
US20090053193A1 (en) 2004-05-11 2009-02-26 Novo Nordisk Healthcare A/G Use of Factor VIIa for the Treatment of Burn Trauma
US8728525B2 (en) * 2004-05-12 2014-05-20 Baxter International Inc. Protein microspheres retaining pharmacokinetic and pharmacodynamic properties
MXPA06012992A (es) * 2004-05-12 2007-02-12 Baxter Int Microesferas que comprenden proteina y que muestran inyectabilidad en altas concentraciones de este agente.
WO2005115442A1 (en) 2004-05-25 2005-12-08 Novo Nordisk Health Care Ag Use of coagulation factor xiii for treatment of post surgical bleedings
EP1748781B1 (en) * 2004-05-27 2012-12-19 Baxter International Inc. Methods for treating bleeding disorders using sulfated polysaccharides
WO2005123916A2 (en) 2004-06-21 2005-12-29 Novo Nordisk Health Care Ag Glycosylation-disrupted factor vii variants
WO2006008267A2 (en) 2004-07-16 2006-01-26 Novo Nordisk Health Care Ag Methods for optimizing forming viiia-based hemostatic treatment
US20060040896A1 (en) 2004-08-18 2006-02-23 Paringenix, Inc. Method and medicament for anticoagulation using a sulfated polysaccharide with enhanced anti-inflammatory activity
BRPI0406057B1 (pt) * 2004-09-15 2021-10-26 União Química Farmacêutica Nacional S/A Sequência nucleotídica de um inibidor de proteases do tipo kunitz obtida a partir de uma biblioteca de cdna de glândulas salivarares de carrapatos amblyomma cajennese uso da proteína recombinante
JP4252954B2 (ja) 2004-12-02 2009-04-08 インターナショナル・ビジネス・マシーンズ・コーポレーション 情報処理装置、情報処理装置のパワーマネージメント方法、およびそのためのプログラム
JP5236952B2 (ja) 2005-02-28 2013-07-17 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト 改善された特性を有するｆｘｉｉｉバリアント
CN101184775A (zh) 2005-03-04 2008-05-21 伊利诺斯大学理事会 凝血及纤溶级联系统的调控剂
AU2006241145B2 (en) * 2005-04-27 2011-04-28 Baxter Healthcare S. A. Surface-modified microparticles and methods of forming and using the same
KR20080008364A (ko) * 2005-05-05 2008-01-23 헤모텍 아게 관 스텐트의 전면 코팅
WO2006128497A1 (en) 2005-06-01 2006-12-07 Novo Nordisk A/S Pharmaceutical formulation of factor xi
US20080161425A1 (en) * 2005-07-29 2008-07-03 Universiteit Van Maastricht Regulation of Tissue Factor Activity by Protein S and Tissue Factor Pathway Inhibitor
DE102005039579B4 (de) * 2005-08-19 2022-06-30 Magforce Ag Verfahren zur Einschleusung von therapeutischen Substanzen in Zellen
GB0525999D0 (en) 2005-12-21 2006-02-01 Ares Trading Sa Novel members of the kazal family of serine protease inhibitors
DE112007000906A5 (de) * 2006-02-09 2009-01-15 B. Braun Melsungen Ag Faltenballonbeschichtungsverfahren
US20070192033A1 (en) * 2006-02-16 2007-08-16 Microsoft Corporation Molecular interaction predictors
WO2007127834A2 (en) 2006-04-26 2007-11-08 Medtronic, Inc. Compositions and methods of preparation thereof
US20070281031A1 (en) 2006-06-01 2007-12-06 Guohan Yang Microparticles and methods for production thereof
EP1892303A1 (en) * 2006-08-22 2008-02-27 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Methods for identifying therapeutical targets in tumors and for determining and targeting angiogenesis and hemostasis related to adenocarcinomas of the lung
EP1895436A1 (en) * 2006-08-31 2008-03-05 Silicos NV Method for evolving molecules and computer program for implementing the same
EP1913962A1 (en) 2006-10-22 2008-04-23 Ophir Perelson Expandable medical device for the treatment and prevention of cardiovascular diseases
CN101663326B (zh) 2007-02-23 2013-03-20 巴克斯特国际公司 从海藻提取物中纯化岩藻依聚糖的工艺方法
EP1972687A1 (en) 2007-03-23 2008-09-24 GenOdyssee Polynucleotides and polypeptides of human factor VII gene, SNPs
US20100137211A1 (en) 2007-04-11 2010-06-03 Monahan Paul E Methods and compositions for intra-articular coagulation proteins
WO2008157824A2 (en) * 2007-06-21 2008-12-24 Conjuchem Biotechnologies Inc. Thrombopoietin peptide conjugates
PT3078743T (pt) 2007-09-28 2020-07-15 Portola Pharm Inc Antídotos para inibidores do fator xa e métodos de utilização dos mesmos
US20100297257A1 (en) 2007-11-09 2010-11-25 National Institutes Of Health (Nih), U.S. Dept. Of Health And Human Services (Dhhs) Anticoagulant antagonist and hemophillia procoagulant
EP2231702A1 (en) 2007-12-21 2010-09-29 Ifxa A/s Protease inhibitor
FR2934052B1 (fr) 2008-07-17 2011-11-25 Stago Diagnostica Dosage de l'activite du facteur tissulaire circulant
UA112050C2 (uk) 2008-08-04 2016-07-25 БАЄР ХЕЛСКЕР ЛЛСі Терапевтична композиція, що містить моноклональне антитіло проти інгібітора шляху тканинного фактора (tfpi)
KR100994996B1 (ko) 2008-08-06 2010-11-18 한국과학기술연구원 페난트렌 노출 여부 확인용 바이오마커 및 이를 이용한확인 방법
MX2011000847A (es) 2008-08-06 2011-02-25 Novo Nordisk Healthcare Ag Proteinas conjugadas con eficacia prolongada in vivo.
JP5739816B2 (ja) 2008-12-19 2015-06-24 バクスター・インターナショナル・インコーポレイテッドＢａｘｔｅｒ Ｉｎｔｅｒｎａｔｉｏｎａｌ Ｉｎｃｏｒｐ０Ｒａｔｅｄ Ｔｆｐｉインヒビターおよび使用法
WO2011115712A2 (en) 2010-03-19 2011-09-22 Baxter International Inc Tfpi inhibitors and methods of use
CA2831907C (en) 2011-04-01 2020-03-24 Bayer Healthcare Llc Monoclonal antibodies against tissue factor pathway inhibitor (tfpi)
EP2808081A4 (en) 2012-01-23 2015-08-26 N E Chemcat Corp BARIUM SULPHATE CONTAINING ALUMINUM MATERIAL AND EXHAUST GAS CLEANING CATALYST THEREOF
JP6153985B2 (ja) 2015-10-16 2017-06-28 株式会社スクウェア・エニックス ビデオゲーム処理プログラム、ビデオゲーム処理システム及びビデオゲーム処理方法

Also Published As

Publication number Publication date
NZ593815A (en) 2013-05-31
US20180072784A1 (en) 2018-03-15
US20130274193A1 (en) 2013-10-17
DK2379096T3 (da) 2019-11-25
BR122021014783B1 (pt) 2023-03-14
SI2379096T1 (sl) 2020-03-31
EP2379096A4 (en) 2012-09-05
LT2379096T (lt) 2019-12-27
CN102348462B (zh) 2015-06-17
US9777051B2 (en) 2017-10-03
WO2010071894A3 (en) 2010-10-07
KR20180137609A (ko) 2018-12-27
CA2747721C (en) 2021-07-20
KR102165021B1 (ko) 2020-10-14
CN104984319A (zh) 2015-10-21
CN104984319B (zh) 2025-05-09
NZ607892A (en) 2014-11-28
ES2773766T3 (es) 2020-07-14
HRP20192282T1 (hr) 2020-03-06
KR101977846B1 (ko) 2019-05-14
US8466108B2 (en) 2013-06-18
CN102348462A (zh) 2012-02-08
AU2009327338A1 (en) 2011-06-30
EP2379096B1 (en) 2019-10-30
JP6095717B2 (ja) 2017-03-15
KR101792032B1 (ko) 2017-11-02
US11001613B2 (en) 2021-05-11
JP2012512915A (ja) 2012-06-07
JP2015178502A (ja) 2015-10-08
HRP20192282T8 (hr) 2020-07-10
JP6567577B2 (ja) 2019-08-28
KR20110134378A (ko) 2011-12-14
CA2747721A1 (en) 2010-06-24
EP2379096A2 (en) 2011-10-26
WO2010071894A2 (en) 2010-06-24
KR20170121334A (ko) 2017-11-01
AU2009327338B2 (en) 2015-07-02
US20100173847A1 (en) 2010-07-08
JP2017095518A (ja) 2017-06-01
HUE046951T2 (hu) 2020-04-28
BRPI0922344A2 (pt) 2017-10-24

Similar Documents

Publication Publication Date Title
JP6567577B2 (ja) Ｔｆｐｉインヒビターおよび使用法
US10124033B2 (en) Peptides and methods of use
AU2017203999B2 (en) Tfpi inhibitors and methods of use
HK1163516A (en) Tfpi inhibitors and methods of use
HK1163516B (en) Tfpi inhibitors and methods of use
EA041584B1 (ru) Пептиды, ингибирующие активность белка s, и их применение для лечения нарушения свертывания крови

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20120220

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20121127

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20121127

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20130913

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20130930

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20130913

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140604

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140902

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140909

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20141204

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20150327

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20150424

R150 Certificate of patent or registration of utility model

Ref document number: 5739816

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250